Chinese medicine for idiopathic Parkinson's disease: A meta analysis of randomized controlled trials.

Wei Wei; Hai-yong Chen; Wen Fan; Shui-fen YE; Yi-hui XU; Jing Cai

Return

Chinese medicine for idiopathic Parkinson's disease: A meta analysis of randomized controlled trials.

Author: Wei WEI ¹ ; Hai-Yong CHEN ² ; Wen FAN ³ ; Shui-Fen YE ⁴ ; Yi-Hui XU ⁵ ; Jing CAI ⁶
Author Information

1. College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.
2. School of Chinese Medicine, the University of Hong Kong, Hong Kong SAR, China.
3. Xiamen Haicang Hospital, Xiamen, Fujian Province, 361026, China.
4. Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, 364000, China.
5. Second People's Hospital, Fujian University of Traditional Chinese Medicine, Fuzhou, 350003, China.
6. College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China. caij1@163.com.
Publication Type:Journal Article
Keywords: Chinese medicine; Parkinson’s disease; meta analysis; randomized controlled trials
MeSH: Humans; Medicine, Chinese Traditional; adverse effects; Parkinson Disease; drug therapy; Publication Bias; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Treatment Outcome
From: Chinese journal of integrative medicine 2017;23(1):55-61
CountryChina
Language:English
Abstract:
OBJECTIVETo evaluate the efficacy of Chinese medicine (CM) adjunct to conventional medications for idiopathic Parkinson's disease (PD).
METHODSElectronic English and Chinese databases including PubMed, Cochrane Library, Web of Science, Chinese Medical Current Contents, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Med Database, and Traditional Chinese Medical Database System were used for key words searching in a highly sensitive search strategy. The extracted data was analyzed by the Review Manager 5.0.
RESULTSTwelve trials involving 869 participants were included in the meta-analysis. Unified PD Rating Scale (UPDRS) I, II, III, IV scores and UPDRS V-IV total scores were used to be the primary outcomes, Parkinson Disease Question-39 (PDQ-39) and Scores of Chinese Medical Symptoms were the secondary outcomes. CM adjunct therapy had greater improvement in UPDRS I [2 trials; standardized mean difference (SMD)-0.40, 95% confidence interval (CI)-0.71 to-0.09; Z=2.49 (P=0.01)], II [5 trials; SMD-0.47, 95% CI-0.69 to-0.25; Z=4.20 (P<0.01)], III [5 trials; SMD-0.35, 95% CI-0.57 to-0.13; Z=3.16 (P=0.002)], IV scores [3 trials; SMD-0.32, 95% CI-0.60 to-0.03; Z=2.17 (P=0.03)], UPDRS I-IV total scores [7 trials; SMD-0.36, 95%CI-0.53 to-0.20; Z=4.24 (P<0.05)]. PDQ-39 and Chinese medical symptoms compared to the conventional medication only.
CONCLUSIONCM adjunct therapy has potential therapeutic benefits by decreasing UPDRS scores and reducing adverse effect.